

National Multiple Sclerosis Society

733 Third Avenue New York, NY 10017-3288

Expert Opinion Paper

National Clinical Advisory Board of the National Multiple Sclerosis Society

Treatment Recommendations for Physicians

Assessment and Management of Cognitive Impairment in Multiple Sclerosis

INTRODUCTION

This document is based on existing literature and expert opinion derived from clinical practice and experience. It is designed to help clinicians be sensitive to the possibility of cognitive deficits in their patients with MS, be more aware of the impact of such deficits, and learn about potential interventions to alleviate the negative consequences of these deficits.

SUMMARY

- ◆ Cognitive deficits appear to be present in more than half of MS patients, however the majority of persons with MS do not have impairments that significantly impair daily functioning.
- ◆ Learning/memory, speed of information processing, working memory, cognitive flexibility and other executive functions appear to be most commonly impaired.
- ◆ Periodic screening for such deficits is recommended.
- ◆ Intervention for such deficits is recommended:
 - Training in strategies to compensate for deficits
 - Counseling/psychotherapy for patients and family to address accompanying behavioral changes and emotional responses, and develop realistic expectations
 - ◆ Treatment with medications (disease-modifying and/or symptomatic therapies)

BACKGROUND

Prevalence of Cognitive Dysfunction and MS

Studies suggest that cognitive impairment may occur in up to 50% of all MS patients *although the* prevalence has not been adequately determined by prospective, population-based studies.^{1,2,3,4} The most common cognitive impairments are:





- ◆ Impaired learning and memory,^{5,6,7,8} i.e., encoding, storage, manipulation, retrieval of information, especially episodic memory (experiential knowledge of events)
- ◆ Slowed information processing, 9,10,11,12 i.e., reductions in speed of thinking that can affect efficiency of cognitive function
- ◆ Impaired working memory,^{13,14} especially alternating attention (or shifting attention back and forth between two stimuli—cognitive flexibility) and complex attention (simultaneously attending to multiple stimuli)
- ◆ While less common, deficits in spatial abilities and higher executive function are recognized and are detrimental to adaptive behavior^{15,16}

Impact of Cognitive Function

Studies have clearly shown that individuals with cognitive decline are at greater risk for employment problems.¹⁷ Those with moderate to severe cognitive dysfunction also have difficulty with activities of daily living, may require personal assistance, and may experience problems in social situations.^{18,19,20} The impact on family relationships is also significant.^{21,22} Furthermore, the impact on driving may be great enough that the individual is no longer safe behind the wheel.^{23,24}

Often patients require cognitive evaluation to determine the extent to which their complaints, or the concerns of others, are related to actual MS related cognitive decline, or other confounding factors such as fatigue, ^{25,26,27} and/or mood disorder. ^{28,29,30} Adherence to medication and other therapeutic regimens may also be affected by cognitive dysfunction; for example, training in injection techniques for disease modifying agents may present greater challenges in patients with cognitive dysfunction.³¹

Correlation between Cognitive Dysfunction and Other MS Characteristics

Cognitive impairment is difficult to predict on the basis of clinical presentation alone.

- ◆ Heterogeneity in cognitive deficits related to different disease courses is well established.^{32,33,34}
- ◆ Based on several studies,^{35,36,37} no or minimal correlation has been found between physical disability and cognitive deficits. In fact, some studies have shown defective cognitive function in patients with minimal physical disability.^{38,39,40}
- ◆ Depression can give rise to deficiency in working-memory capacity.⁴¹
- ◆ Correlation between cognitive dysfunction and fatigue has been observed in some studies although not consistently.^{42,43} In one study, subjective fatigue across the workday increased more for MS patients than for a control group but cognitive test performance was equal for the two groups.⁴⁴
- ◆ There is an ambiguous relationship between disease duration and cognition. Some researchers find correlation between length of disease and cognitive status, while others find no relationship. 45,46,47

◆ A recent study showed a gender-related effect of clinical and genetic variables on cognitive impairment in MS. Cognitive decline was predominant in men and was associated with clinical and genetic variables while cognitive dysfunction in women was independent of these variables.48

MRI Findings and Cognitive Dysfunction

While many factors can contribute to cognitive impairment (e.g., depression, premorbid ability), the strong relationship between neuropsychological testing and brain MRI demonstrates that much of the problem is due to cerebral disease (recent studies show large effects on the order of $r = 0.71^{49,50}$).

- ◆ Many studies have shown that lesion volume is correlated with cognitive dysfunction in MS, 51,52,53,54,55
- ◆ Stronger correlations have emerged with measures of brain atrophy, ^{56,57} and cognitive deterioration depends more on the development of brain parenchymal atrophy than on the extent of lesion burden in the brain.58
- ◆ There are other promising MRI indicators that account for cognitive declines in MS, such as regional brain atrophy,⁵⁹ diffusion-tensor imaging,⁶⁰ and N-acetylaspartate (NAA—indicative of axonal integrity) levels,⁶¹ to name a few.

A goal for future research is to develop reliable neuroimaging methods that may be used to identify patients at risk for cognitive impairment. 62,63,64

RECOMMENDATIONS

Recommendations for Screening and Assessment

◆ Providers should consider periodic screening and/or assessment for cognitive deficits in **MS, as such deficits may not be always be apparent or reported.** Cognitive dysfunction may be difficult to detect because language skills and intellectual function are generally preserved. 65 Because of the high incidence of cognitive impairment in MS, its potentially devastating consequences, as well as the advent of new therapies, periodic screening (e.g., every 1–2 years) is recommended. Screening refers to the application of a simple, inexpensive test that attempts to identify patients that (a) may have a specified illness or condition and (b) would benefit from further evaluation (and in turn, treatment).

Recommended approaches:

- Query the patient as well as the family regarding cognitive function. Report by family members is closely correlated to cognitive deficits in the individual with MS.⁶⁶ Note that patient reports that are not confirmed by the family may reflect elevated depressive symptoms (e.g., poor self image) rather than true or measurable cognitive deficits. On the other hand, patients may not report symptoms that the family recognizes.
- Utilize self- and informant-report questionnaires The most appropriate self-report instrument available at this time is the MS Neuropsychological Screening Questionnaire (MSNQ). This

is a brief (5-minute) questionnaire that is completed by the patient and by a family member, and does not require a neuropsychologist or rehabilitation professional to administer or score.⁶⁷

Several other methods for screening for cognitive impairment have been proposed. (See tables below.) Financial and time constraints in an outpatient practice may limit the use of these instruments.

Examples of MS Screening Methods (in order of time requirements)				
Name	First Author	Description	Recommended Administrator	
Screening Examination for Cognitive Impairment in MS	W. Beatty (1995)	Brief selection of NP tests emphasizing tests of attention, memory and problem-solving requiring 25–30 min.	Neuropsychologist, or other qualified rehabilitation specialist (e.g., occupational therapist, speech/language pathologist, nurse practitioner, etc.)	
Neuropsychological Screening Battery for MS	S. Rao (1991)	Brief selection of NP tests emphasizing processing speed and memory requiring 30–35 min.	Neuropsychologist, or other qualified rehabilitation specialist (e.g., occupational therapist, speech/language pathologist, nurse practitioner, etc.)	
Automated Neuropsychological Assessment Metrics—ANAM	J. Wilken (2003)	A computerized selection of NP tasks emphasizing tests of reaction time, processing speed, working memory, recognition memory, visual reasoning, and fine motor coordination requiring approximately 30 min.	Neuropsychologist, or other qualified rehabilitation specialist (e.g., occupational therapist, speech/language pathologist, nurse practitioner, etc.)	

Examples of MS Brief NP Test Batteries (in order of time requirements)				
Name	First Author	Description		
Brief Repeatable Battery of Neuropsychological Tests in MS (BRB)	S. Rao (1991)	Tests were empirically derived from a larger battery of NP tests. Included are the Paced Auditory Serial Addition Test, Symbol Digit Modalities Test, Selective Reminding Test, 10/36 Spatial Recall Test, and the Controlled Oral Word Association Test. Approximate administration time 60 min.		
Minimal Assessment of Cognitive Function in MS (MACFIMS)	R. Benedict (2002)	Tests were rationally derived based on a consensus conference sponsored by the Consortium of MS Centers. Included are the Paced Auditory Serial Addition Test, Symbol Digit Modalities Test, California Verbal Learning Test—II, Brief Visuospatial Memory Test—Revised, Judgment of Line Orientation Test, Controlled Oral Word Association Test, and the Sorting Test from the Delis-Kaplan Executive Function System. Approximate administration time 90 min.		

The evaluation approach should be tailored to the clinical needs of the patient or clinic. Brief objective testing batteries have been proposed for MS patients with known or suspected cognitive deficits.^{68,69} There is also increasing interest in the use of single neuropsychological tests that can be administered to identify patients who are cognitively impaired.^{70,71}

Neuropsychological data can help identify areas of cognitive or behavioral change for such at-risk patients, and provide baseline data for later comparisons. However, before neuropsychological deficits are ascribed to multiple sclerosis, the influence of other medical conditions and medications should be considered.

In certain circumstances, *comprehensive* neuropsychological evaluation is appropriate to consider, including detailed exploration of deficits commonly associated with multiple sclerosis.⁷² Other forms of cognitive evaluation may be administered by occupational and speech/language therapists (as well as other health care providers) as part of the assessment process, and to guide clinical care.

The most common indicators for comprehensive neuropsychological evaluation are:

1. *Maintenance of employment*

Patients struggling to maintain competitive employment. These patients need a detailed review of residual strengths as well as weaknesses, so effective treatment can be designed and delivered, and appropriate accommodations made in the workplace. Some patients may be denied disability benefits on the basis of normal IQ testing, which lacks sensitivity to MS-associated cognitive impairment. It is important to evaluate higher executive functions in such patients.

2. *Independence in home and community*

Patients struggling with family or household management, and/or activities of daily living benefit from a clear delineation of neurocognitive and neurobehavioral strengths and weaknesses.

3. Educational attainment

Students of all ages whose educational activities require cognitive acumen, and who would benefit from knowing how their residual abilities and difficulties are likely to impact success in school, are also well served by more comprehensive neuropsychological evaluation. Test results also help guide recommendations for accommodation in the classroom.

4. *Differential diagnosis, and/or co-morbid conditions*

Consider additional testing where it is necessary to rule out other neurological conditions such as Alzheimer's disease or depression. In addition, for some patients, the level of psychiatric distress or symptoms they develop may interfere with effective cognitive function, even though major cognitive deficits are not present.

Cognitive *re*-evaluation is often recommended to ascertain whether there is evidence of cognitive decline. Other clinical problems related to longitudinal analysis include:

- 1) Significant cognitive worsening has occurred, accompanied by a major depressive episode; testing is needed to differentiate probable neurocognitive changes from mood disorder, to help guide pharmacologic and other treatments.
- 2) Cognitive function has continued to worsen in an older patient with MS, despite disease modifying therapies that have helped maintain physical function; there are concerns about a new, underlying cortical dementia such as Alzheimer's disease.
- 3) A patient, placed on medical leave from work secondary to cognitive problems at the time of a major exacerbation, has improved, and the employer requests documentation of current abilities to assist with successful return to work efforts.

Recommendations for Intervention and Management

- ◆ Intervention and management of cognitive dysfunction in MS is ideally performed by certified and/or licensed health professionals experienced in cognitive rehabilitation, with medication management provided by physicians or other appropriate health care providers, e.g., nurse practitioners. Cognitive rehabilitation professionals include neuropsychologists, psychologists, speech-language pathologists, and occupational therapists. The physicians involved in medication management for cognitive problems are typically neurologists, psychiatrists, or physiatrists (rehabilitation medicine physicians). Ideally, these professionals should have an understanding of MS, including the disease process, common symptoms and findings, and medical treatments (and their side effects). In addition, an understanding of factors that may aggravate or complicate assessment, treatment and function of people with MS—especially temperature-sensitivity, fatigue, and affective disturbance—is desirable.
- Interventions should be designed to improve the person's ability to function in all meaningful aspects of family and community life. Intervention should involve systematic, functionally-oriented, therapeutic activities that are based on understanding of specific deficits. Most commonly, compensatory strategies (i.e., utilizing intact skills and/or external aids) are used to improve daily functioning. Examples include: cognitive structuring (a learned, practiced approach used to routinize cognitive tasks); substitution strategies (the learned use of intact cognitive abilities to circumvent or bolster impaired abilities, such as using intact visual memory in place of impaired verbal memory function); scheduling and timelines; use of recording devices; memory strategies (e.g., lists, mnemonics, clustering, visualization techniques); templates for repeated tasks; organizational strategies; assistive technology (e.g., hand held computers, electronic calendars and memory logs), creating a structured environment; conducting conversations and activities in quiet places to minimize distraction; etc. Solution-focused, practical training in how to maximize function in spite of deficits, which can be generalized to the individual's everyday environment, is most desirable.

Therapeutic activities designed to restore function (e.g., direct retraining) have also been attempted. However, evidence of effectiveness is ambiguous and controversial. Although the main body of literature suggests some benefit of intervention for people with MS, 73,74,75,76,77,78,79,80 other studies have not demonstrated a benefit. 81,82,83 Furthermore, improvement of scores on standardized tests may not necessarily be correlated with improved function in everyday work or avocational situations.

- ◆ In some circumstances, interventions should be accompanied by counseling/psychotherapy to address grief, decreased self-esteem, anxiety, and other emotional responses that may accompany cognitive deficits. Concurrent emphasis on helping the individual redefine him/her-self, develop effective coping strategies, increase communication skills, and learn to take fullest advantage of his/her strengths to compensate for new areas of difficulties is paramount. Involvement of family members in counseling is critical; in order to facilitate the individual's accommodation to deficits, families need to adjust their expectations to reflect those deficits.
- ◆ Like other clinical manifestations of MS, cognitive impairment—and especially worsening cognitive impairment as indicated by cognitive testing—is a sign of active disease, and should be viewed as justification for using disease modifying therapy or changing to a different immunomodulator, as well as other medications that may address cognitive symptoms. (For further clarification on the use of disease modifying agents, see the Society's Disease Management Consensus Statement.⁸⁴) In patients who have dementia (some 10%–20% of MS patients⁸⁵), medications shown to be effective for Alzheimer's disease and other types of dementia are appropriate.^{86,87,88} These same medications show promise for mild cognitive impairment more often seen in patients with MS. A recent trial with Donepezil HCl suggested improvement in many aspects of cognitive function^{70,89} though a smaller, earlier trial did not.⁹⁰ No benefit was found with the use of amantadine or 4-Aminopyridine in some studies^{91,92} while improved attention was found in another.⁹³ Symptomatic treatment of fatigue and depression may also yield improvement in functional cognitive abilities.

Recommendations for Future Research

More research is needed to further evaluate cognitive rehabilitation and intervention in people with MS across the spectrum of the illness.

Issues to be addressed include:

- Better outcome measures
- ◆ The role that individualized assessment might play before treatment
- ◆ Specific evaluation and treatment techniques
- Duration of treatment
- Duration of benefits.

REFERENCES

- 1. Bobholtz JA, Rao SM. Cognitive dysfunction in MS: A review of recent developments. *Current Opinion in Neurology* 2003; 16:283–288.
- 2. Heaton RK. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. *Journal of Consulting & Clinical Psychology* 1985; 53:103–110.
- 3. Peyser JM, Edwards KR, Poser CM, Filskov SB. Cognitive function in patients with multiple sclerosis. *Archives of Neurology* 1980; 37:577–579.

- 4. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. *Neurology* 1991; 41:685–691.
- 5. Fischer JS. Using the Wechsler Memory Scale—Revised to detect and characterize memory deficits in multiple sclerosis. *Clinical Neuropsychology* 1988; 2:149–172.
- 6. Rao SM. Neuropsychology of multiple sclerosis: A critical review. *Journal of Clinical and Experimental Neuropsychology* 1986; 8:503–452.
- 7. DeLuca J, Barbieri-Berger S, Johnson SK. The nature of memory impairments in multiple sclerosis: Acquisition versus retrieval. *Journal of Clinical and Experimental Neuropsychology* 1994; 16:183–189.
- 8. Amato MP, Ponzini G, Siracusa G, Sorbi S. Cognitive dysfunction in early onset MS: A reappraisal after 10 years. *Archives of Neurology* 2001; 58:1602–1606.
- 9. Rao SM, Leo GJ, St. Aubin-Farbert P. Information processing speed in patients with multiple sclerosis. *Journal of Clinical and Experimental Neuropsychology* 1989; 11:471–477.
- 10. DeLuca J, Johnson SK, Natelson BH. Information processing efficiency in chronic fatigue syndrome and multiple sclerosis. *Archives of Neurology* 1993; 50:301–304.
- 11. Archibald CJ, Fisk JD. Information processing efficiency in patients with multiple sclerosis. Journal of Clinical and Experimental Neuropsychology 2000; 22:686–701.
- 12. De Sonneville LM. Information processing characteristics in subtypes of MS. *Neuropsychologia* 2002; 40:1751–1765.
- 13. Rao SM, Grafman J, DiGiulio D, Mittenberg W, Bernardin L, Leo GJ, Luchetta T, Unveragt F. Memory dysfunction in multiple sclerosis: Its relation to working memory, semantic encoding, and implicit learning. *Neuropsychology* 1993; 7:364–374.
- 14. Fisk JD, Archibald CJ. Limitations of the Paced Auditory Serial Addition Test as a measure of working memory in patients with multiple sclerosis. *Journal of the International Neuropsychological Society* 2001; 7:363–372.
- 15. Beatty WW, Monson N. Problem solving by patients with multiple sclerosis: Comparison of performance on the Wisconsin and California Card Sorting Test. *Journal of the International Neuropsychological Society* 1996; 2:134–140.
- Foong J, Rozewicz L, Quaghebeur G, Davie CA, Kartsounis LD, Thompson AJ, Miller DH, Ron MA. Executive function in multiple sclerosis: The role of frontal lobe pathology. *Brain* 1997; 120:15–26.
- 17. Beatty WW, Blanco CR, Wilbanks SL, Paul RH. Demographic, clinical, and cognitive characteristics of multiple sclerosis patients who continue to work. *Journal of Neurological Rehabilitation* 1995; 9:167–173.
- 18. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. *Neurology* 1991; 41(5):692–696.

- 19. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. *Journal of the Neurological Sciences* 2005; 231(1–2):29–34.
- 20. Wild KV, Lezak M, Whitman RH, Bourdette DN. Psychosocial impact of cognitive impairment in the multiple sclerosis patient. *Journal of Clinical and Experimental Neuropsychology* 1991; 13:74.
- 21. Hakim EA, Bakheit AM, Bryant TN, Roberts MWH, McIntosh-Michaelis SA, Spackman AJ, Martin JP, McLellan DL. The social impact of multiple sclerosis—A study of 305 patients and their relatives. *Disability & Rehabilitation* 2000; 22(6):288–293.
- 22. Knight RG, Devereux RC, Godfrey HPD. Psychosocial consequences of caring for a spouse with multiple sclerosis. *Journal of Clinical and Experimental Neuropsychology* 1997; 19:7–19.
- 23. Schultheis MT, Garay E, Millis SR, DeLuca J. Motor vehicle crashes and violations among drivers with multiple sclerosis. *Archives of Physical Medicine & Rehabilitation* 2002; 83:1175–1178.
- 24. Schultheis MT, Garay E, DeLuca J. The influence of cognitive impairment on driving performance in multiple sclerosis. *Neurology* 2001; 56:1089–1094.
- 25. Krupp LB, Sliwinski M, Masur DM, Friedberg F, Coyle PK. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. *Archives of Neurology* 1994; 51:705–710.
- 26. Krupp LB. Fatigue and declines in cognitive functioning in multiple sclerosis. *Neurology* 2000; 55:934–939.
- 27. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Archives of Neurology* 1989; 46:1121–1123.
- 28. Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. Depression in multiple sclerosis: Relationship to working memory capacity. *Neuropsychology* 1999; 13:546–556.
- 29. Patten SB, Metz LM. Depression in multiple sclerosis. *Psychotherapy and Psychosomatics* 1997; 66:286–292.
- 30. Mohr DC, Goodkin DE, Gatto N, van der Wende J. Depression, coping and level of neurological impairment in multiple sclerosis. *Multiple Sclerosis* 1997; 3:254–258
- 31. Holland N, Weisel P, Cavallo P, Edwards C, Halper J, Kalb R, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part 1. *Rehabilitation Nursing* 2001; 26(5):172–176.
- 32. Wachowius UJ. Cognitive impairment in primary and secondary progressive MS. *Journal of Clinical and Experimental Neuropsychology* 2005; 27:65–77.
- 33. Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. *Neurology* 2004; 63(2):335–339.

- 34. De Sonneville LM. Information processing characteristics in subtypes of MS. *Neuropsychologia* 2002; 40:1751–1765.
- 35. Beatty WW, Goodkin DE, Hertsgaard D, Monson N. Clinical and demographic predictors of cognitive performance in multiple sclerosis: Do diagnostic type, disease duration, and disability matter? *Archives of Neurology* 1990; 47(3):305–308.
- 36. Peyser JM, Edwards KR, Poser CM. Psychological profiles in patients with multiple sclerosis: A preliminary investigation. *Archives of Neurology* 1980; 37:437–440.
- 37. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. *Neurology* 1991; 41(5):692–696.
- 38. Olivares T, Nieto A, Sánchez MP, Wollmann T, Hernández MA, Barroso J. Pattern of neuropsychological impairment in the early phase of relapsing-remitting multiple sclerosis. *Multiple Sclerosis* 2005; 11:191–197.
- 39. Van Den Burg W, van Zomeren H, Minderhoud JM, Prange AJ, Meijer NS. Cognitive impairment in patients with multiple sclerosis and mild physical disability. *Archives of Neurology* 1987; 44:494–501.
- 40. Haase CG, Tinnefeld M, Lienemann M, Ganz RE, Faustmann PM. Depression and cognitive impairment in disability-free early multiple sclerosis. *Behavioral Neurology* 2003; 14(1–2):39–45.
- 41. Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. Depression in multiple sclerosis: Relationship to working memory capacity. *Neuropsychology* 1999; 13:546–556.
- 42. Frazer C, Stark S. Cognitive symptoms and correlates of physical disability in individuals with multiple sclerosis. *Journal of Neuroscience Nursing* 2003; 35:314–320.
- 43. Krupp LB. Fatigue and declines in cognitive functioning in multiple sclerosis. *Neurology* 2000; 55:934–939.
- 44. Beatty WW, Goretti B, Siracusa G, Zipoli V, Portaccio E, Amato MP. Changes in neuropsychological test performance over the workday in multiple sclerosis. *Clinical Neuropsychology* 2003; 17(4):551–560.
- 45. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. *Neurology* 1991; 41(5):692–696.
- 46. Peyser JM, Edwards KR, Poser CM, Filskov SB. Cognitive function in patients with multiple sclerosis. *Archives of Neurology* 1980; 37:577–579.
- 47. Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing/remitting and chronic progressive multiple sclerosis. *Journal of Consulting and Clinical Psychology* 1985; 53:103–110.
- 48. Saviettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, et al. Gender related effect of clinical and genetic variables on the cognitive impairment in MS. *Journal of Neurology* 2004; 251:1208–1214.

- 49. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R, et al. Prediction of neuropsychological impairment in multiple sclerosis: Comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. *Archives of Neurology* 2004; 61(2):226–230.
- 50. Christodoulou C, Krupp LB, Liang Z, Huang W, Melville P, Roque C, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. *Neurology* 2003; 60(11):1793–1798.
- 51. Franklin GM, Heaton RK, Nelson LM, Filley CM, Seibert C. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. *Neurology* 1988; 38(12):1826–1829.
- 52. Fulton JC, Grossman RI, Udupa J, Mannon LJ, Grossman M, Wei L, Polansky M, Kolson DL. MR lesion load and cognitive function in patients with relapsing-remitting multiple sclerosis. *American Journal of Neuroradiology* 1999; 20(10):1951–1955.
- 53. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R, et al. Prediction of neuropsychological impairment in multiple sclerosis: Comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. *Archives of Neurology* 2004; 61(2):226–230.
- 54. Christodoulou C, Krupp LB, Liang Z, Huang W, Melville P, Roque C, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. *Neurology* 2003; 60(11):1793–1798.
- 55. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. *Neurology* 1989; 39(2 Pt 1):161–166.
- 56. Christodoulou C, Krupp LB, Liang Z, Huang W, Melville P, Roque C, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. *Neurology* 2003; 60(11):1793–1798.
- 57. Pozzilli C, Bastianello S, Padovani A, Passafiume D, Millefiorini E, Bozzao L, Fieschi C. Interior corpus callosum atrophy and verbal fluency in multiple sclerosis. *Cortex* 1991; 27(3):441–445.
- 58. Benedict RH, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. *Journal of Neuroimaging* 2004; 14(3 Suppl):36S–45S.
- 59. Benedict RHB, Zivadinov R, Carone D, Weinstock-Guttman B, Gaines J, Maggiore C, et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. *American Journal of Neuroradiology* 2005; 26:1824–1831.
- 60. Rovaris M, Iannucci G, Falautano M, Possa F, Martinelli V, Comi G, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: An exploratory study with diffusion tensor MR imaging. *Journal of Neurological Science* 2002; 195:103–109.
- 61. Pan JW, Krupp LB, Elkins LE, Coyle PK. Cognitive dysfunction lateralizes with NAA in multiple sclerosis. *Applied Neuropsychology* 2001; 8:155–160.

- 62. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R, et al. Prediction of neuropsychological impairment in multiple sclerosis: Comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. *Archives of Neurology* 2004; 61(2):226–230.
- 63. Carone DA, Benedict RH, Dwyer MG, Cookfair DL, et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. *NeuroImage* 2006; 29(2):505-514.
- 64. Benedict RHB, Bakshi R, Simon JH, Priore R, Miller C, Munschauer F. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. *Journal of Neuropsychiatry and Clinical Neurosciences* 2002; 14:44–51.
- 65. Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995; 8:216–220.
- 66. Benedict RHB, Cox D, Thompson LL, Foley FW, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. *Multiple Sclerosis* 2004; 10(6):675–678.
- 67. Benedict RHB, Munschauer FE, Linn R, Miller C, Foley FW, Jacobs LD. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. *Multiple Sclerosis* 2003; 9:95–101.
- 68. Rao SM. Neuropsychological screening battery for multiple sclerosis. Unpublished manuscript, Section of Neuropsychology, Department of Neurology, Medical College of Wisconsin. 1991.
- 69. Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). *Neurology* 1995; 45:718–723.
- 70. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. *Neurology* 2004 Nov 9; 63(9):1579–1585.
- 71. Deloire M, Bonnet M, Salort E, Arimone Y, Boudineau M, Petry K, Brouchet B. The Symbol Digit Modalities Test: A simple test to select early relapsing remitting multiple sclerosis patients for a complete cognitive evaluation. *Multiple Sclerosis* 2005; 11(Suppl 1):66–75.
- 72. Pepping M, Ehde D. Neuropsychological evaluation and treatment of multiple sclerosis: the importance of a neuro-rehabilitation focus. *Phys Med Rehabil Clin N Am* 2005 May; 16(2):411–436.
- 73. Jonsson A, Korfitzen EM, Heltberg A, Ravnborg MH, Byskov-Ottosen E. Effects of neuropsychological treatment in patients with multiple sclerosis. *Acta Neurologica Scandinavica* 1993; 88(6):394–400.
- 74. Rodgers D, Khoo K, MacEachen M, Oven M, Beatty WW. Cognitive therapy for multiple sclerosis: A preliminary study. *Alternative Therapies in Health and Medicine* 1996; 2(5):70–74.
- 75. Allen DN, Goldstein G, Heyman RA, Rondinelli, T. Teaching memory strategies to persons with multiple sclerosis. *Journal of Rehabilitation Research and Development* 1998; 35(4):405–410.

- 76. Benedict RHB, Shapiro A, Priore RL, Miller C, Munschauer FE, Jacobs LD. Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients. *Multiple Sclerosis* 2001; 6:391–396.
- 77. Chiaravalloti ND, DeLucca J, Moore NB, Ricker JH. Treating learning impairments improves memory performance in multiple sclerosis: A randomized clinical trial. *Multiple Sclerosis* 2005; 11:58–68.
- 78. Plohmann AM, Kappos L, Ammann W, Thordai A, Wittwer A, Huber S, Bellaiche Y, Lechner-Scott J. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry* 1998; 64:455–462.
- 79. Chiaravalloti N, DeLuca J. Self-generation as a means of maximizing learning in multiple sclerosis: An application of the generation effect. *Archives of Physical Medicine and Rehabilitation* 2002; 83:1070–1079.
- 80. LaRocca N. Kalb R, Smith C, Elkin R et al. Comprehensive rehabilitation of cognitive dysfunction in multiple sclerosis. *Multiple Sclerosis* 1998; 4(5): 460.
- 81. Shepko AG, Hollenbeck MA. Comparison of treatment duration for remediation of memory impairment in individuals with multiple sclerosis. *Multiple Sclerosis* 1997; 3:208. (Consortium of Multiple Sclerosis Centers Abstracts)
- 82. Lincoln NB, Dent A, Harding J, Weyman N, Nicholl C, Blumhardt LD, Playford ED. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry* 2002; 72:93–98.
- 83. Solari A, Motta A, Mendozzi L, Pucci E, Forni M, Mancardi G, Pozzilli C. Computer-aided retraining of memory and attention in people with multiple sclerosis: A randomized, double-blind controlled trial. *Journal of the Neurological Sciences* 2004; 222(1–2):99–104. Erratum in *Journal of the Neurological Sciences* 2004; 224(1–2):113.
- 84. Medical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. 2005. Retrieved October 2005 from http://www.nationalmssociety.org/pdf/forpros/Exp_Consensus.pdf.
- 85. 86. Benedict RH, Bobholz J. Multiple sclerosis. Seminars in Neurology 2007; 27(1):78-85
- 86. Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB. Effects of donepezil on memory and cognition in multiple sclerosis. *J Neurol Sci* 2006; 15;245(1-2):127-136.
- 87. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. *Brain Injury* 1998; 12(1):77–80.
- 88. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet* 2002; 359(9314):1283–1290.
- 89. Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, Noviasky J. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. *Journal of Clinical Psychopharmacology* 2000; 20(3):350–356.

- 90. Rorie KD, Stump DA, Jeffery DR. Effects of Donepezil on cognitive function in patients with multiple sclerosis. *Neurology* 2001; 56(Suppl 3):A99.
- 91. Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study. *Neurology* 1994; 44(9):1701–1705.
- 92. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. *Archives of Neurology* 1996; 53(2):185–188.
- 93. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with MS. *Neurology* 1989; 46:676–680.

NMSS Cognition and MS Task Force

Ralph H. B. Benedict, PhD, ABPP-CN, Chairman

Aliza Ben-Zacharia, RN, CRRN, MSN, ANP-C

Patricia A. Bednarik, MS, CCC-SLP

Francois Bethoux, MD

Julie A. Bobholz, PhD

Lauren S. Caruso, PhD

Nancy D. Chiaravalloti, PhD

Christopher Christodoulou, PhD

Debra Frankel, MS, OTR

Jacqueline Hall MS, OTR/L

Nancy Holland, EdD

George H. Kraft, MD

Lauren Krupp, MD

Nicholas LaRocca, PhD

Robert Mendoza, PhD

Mary Pepping, PhD, ABPP-CN

Ken Seaman MA, PT, ACCE

Randy Schapiro, MD